WeVote
Log In

Bill

Bill

SB 1402

essential drugs; price increases; limits.

57th Legislature - First Regular Session Introduced by Lela Alston and 5 co-sponsors

Arizona bill caps year-over-year price increases on essential prescription drugs to improve medication affordability for residents while potentially affecting pharmaceutical investment incentives.

Senate Second Reading
0
WeVote Research Nonpartisan
Bill Summary · SB 1402

Legislative bill overview

SB 1402 proposes to limit price increases on essential drugs in Arizona by capping how much pharmaceutical manufacturers can raise prices year-over-year. The bill aims to make critical medications more affordable for Arizona residents while maintaining incentives for drug development. The specific price increase thresholds and implementation mechanisms would be detailed in the bill's full text.

Why is this important

Drug affordability is a significant healthcare burden for millions of Americans, with many patients rationing medications due to cost. Arizona residents, particularly seniors and those with chronic conditions, struggle with escalating prescription costs that can exceed inflation rates. Price regulation could improve medication access but might affect pharmaceutical companies' pricing strategies and investment in new drugs.

Potential points of contention

  • Drug company opposition: Pharmaceutical manufacturers argue that price controls reduce innovation incentives and profitability needed for research and development
  • Implementation challenges: Determining which drugs qualify as "essential," setting appropriate price caps, and enforcing compliance across supply chains could prove administratively complex
  • Market effects: Price caps might discourage new drug launches in Arizona, limit generic competition, or trigger companies to adjust pricing strategies in other states

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.